Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis
Introduction This literature review and exploratory network meta-analysis (NMA) aimed to compare the clinical effectiveness and tolerability of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres, regorafenib (REG), trifluridine–tipiracil (TFD/TPI), and best supportive care (BSC) in adult patients with chemotherapy-refractory or chemotherapy-intolerant metastatic colorectal cancer (mCRC). Methods In light of recently published data, the literature was searched to complement and update a review published in 2018. Studies up to December 2022 comparing two or more of the treatments and reporting overall survival (OS), progression-free survival (PFS), or incidence of adverse events (AE) were included. The NMA compared hazard ratios (HRs) for OS and PFS using Markov chain Monte Carlo techniques. Results Fifteen studies were included, with eight studies added (none addressing SIRT). All active treatments improved OS in relation to BSC. SIRT had the longest OS among all treatments, although without statistically significant differences (HR [95% credible interval] for SIRT, 0.48 [0.27, 0.87]; TFD/TPI, 0.62 [0.46, 0.83]; REG, 0.78 [0.57, 1.05]) in a fixed effects model. Information regarding SIRT was insufficient for PFS analysis, and TFD/TPI was the best intervention (HR 2.26 [1.6, 3.18]). One SIRT study reported radioembolization-induced liver disease in > 10% of the sample; this was symptomatically managed. Non-haematological AEs (hand-foot skin reaction, fatigue, diarrhoea, hypertension, rash or desquamation) were more common with REG, while haematological events (neutropoenia, leukopenia, and anaemia) were more common with TFD/TPI. Conclusion Current evidence supports SIRT treatment in patients with chemotherapy-refractory or chemotherapy-intolerant mCRC compared to newer oral agents, with comparable OS and low incidence of AEs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Advances in therapy - 41(2024), 4 vom: 26. Feb., Seite 1606-1620 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Azeredo-da-Silva, André L. F. [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Best supportive |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1007/s12325-024-02800-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055270344 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055270344 | ||
| 003 | DE-627 | ||
| 005 | 20240325061004.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240325s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12325-024-02800-5 |2 doi | |
| 035 | |a (DE-627)SPR055270344 | ||
| 035 | |a (SPR)s12325-024-02800-5-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Azeredo-da-Silva, André L. F. |e verfasserin |0 (orcid)0000-0002-5848-1180 |4 aut | |
| 245 | 1 | 0 | |a Selective Internal Radiation Therapy Using Y-90 Resin Microspheres for Metastatic Colorectal Cancer: An Updated Systematic Review and Network Meta-Analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Introduction This literature review and exploratory network meta-analysis (NMA) aimed to compare the clinical effectiveness and tolerability of selective internal radiation therapy (SIRT) using yttrium-90 (Y-90) resin microspheres, regorafenib (REG), trifluridine–tipiracil (TFD/TPI), and best supportive care (BSC) in adult patients with chemotherapy-refractory or chemotherapy-intolerant metastatic colorectal cancer (mCRC). Methods In light of recently published data, the literature was searched to complement and update a review published in 2018. Studies up to December 2022 comparing two or more of the treatments and reporting overall survival (OS), progression-free survival (PFS), or incidence of adverse events (AE) were included. The NMA compared hazard ratios (HRs) for OS and PFS using Markov chain Monte Carlo techniques. Results Fifteen studies were included, with eight studies added (none addressing SIRT). All active treatments improved OS in relation to BSC. SIRT had the longest OS among all treatments, although without statistically significant differences (HR [95% credible interval] for SIRT, 0.48 [0.27, 0.87]; TFD/TPI, 0.62 [0.46, 0.83]; REG, 0.78 [0.57, 1.05]) in a fixed effects model. Information regarding SIRT was insufficient for PFS analysis, and TFD/TPI was the best intervention (HR 2.26 [1.6, 3.18]). One SIRT study reported radioembolization-induced liver disease in > 10% of the sample; this was symptomatically managed. Non-haematological AEs (hand-foot skin reaction, fatigue, diarrhoea, hypertension, rash or desquamation) were more common with REG, while haematological events (neutropoenia, leukopenia, and anaemia) were more common with TFD/TPI. Conclusion Current evidence supports SIRT treatment in patients with chemotherapy-refractory or chemotherapy-intolerant mCRC compared to newer oral agents, with comparable OS and low incidence of AEs. | ||
| 650 | 4 | |a Best supportive |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Liver metastasis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Regorafenib |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SIRT |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Trifluridine–tipiracil |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a de Jesus, Victor Hugo F. |0 (orcid)0000-0003-4702-116X |4 aut | |
| 700 | 1 | |a Agirrezabal, Ion |0 (orcid)0000-0003-3170-7845 |4 aut | |
| 700 | 1 | |a Brennan, Victoria K. |0 (orcid)0000-0001-7814-2306 |4 aut | |
| 700 | 1 | |a Carion, Phuong L. |0 (orcid)0009-0000-2565-8085 |4 aut | |
| 700 | 1 | |a Amoury, Nathalie |0 (orcid)0009-0005-2556-4325 |4 aut | |
| 700 | 1 | |a Vetromilla, Bruna M. |0 (orcid)0000-0002-5520-0865 |4 aut | |
| 700 | 1 | |a Zanotto, Bruna S. |0 (orcid)0000-0003-4012-1395 |4 aut | |
| 700 | 1 | |a Shergill, Suki |0 (orcid)0000-0001-5319-6770 |4 aut | |
| 700 | 1 | |a Ziegelmann, Patricia K. |0 (orcid)0000-0002-2851-2011 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Advances in therapy |d Springer Healthcare, 2000 |g 41(2024), 4 vom: 26. Feb., Seite 1606-1620 |w (DE-627)SPR024919926 |w (DE-600)2421646-X |x 1865-8652 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2024 |g number:4 |g day:26 |g month:02 |g pages:1606-1620 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s12325-024-02800-5 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2024 |e 4 |b 26 |c 02 |h 1606-1620 | ||